These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 23184079)

  • 1. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
    Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
    Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
    Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
    Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
    Perez EA; Romond EH; Suman VJ; Jeong JH; Sledge G; Geyer CE; Martino S; Rastogi P; Gralow J; Swain SM; Winer EP; Colon-Otero G; Davidson NE; Mamounas E; Zujewski JA; Wolmark N
    J Clin Oncol; 2014 Nov; 32(33):3744-52. PubMed ID: 25332249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ?
    Wong FY; Yip CS; Chua ET
    World J Surg; 2012 Feb; 36(2):287-94. PubMed ID: 22105650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab.
    Li S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
    Breast; 2020 Dec; 54():235-241. PubMed ID: 33166784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.
    Zhang GC; Qian XK; Guo ZB; Ren CY; Yao M; Li XR; Wang K; Zu J; Liao N
    Med Oncol; 2012 Dec; 29(5):3222-31. PubMed ID: 22547076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
    de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
    Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
    Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
    Sukumar JS; Sardesai S; Ni A; Williams N; Johnson K; Quiroga D; Ramaswamy B; Wesolowski R; Cherian M; Stover DG; Gatti-Mays M; Pariser A; Sudheendra P; George MA; Lustberg M
    Cancer Med; 2024 Jun; 13(12):e7317. PubMed ID: 38895891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.
    Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S
    Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
    Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
    Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology.
    Uyeturk U; Oksuzoglu B; Akman T; Turker I; Sener N; Tastekin D; Bal O; Berk V; Arslan UY; Urakci Z; Bilir C; Yilmaz U; Yazilitas D; Ulas A; Sonmez OU; Budakoglu B; Cihan S; Uysal M
    Med Oncol; 2014 Apr; 31(4):929. PubMed ID: 24659267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
    Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
    Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
    Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
    J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
    Sammons S; Sedrak MS; Kimmick GG
    Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
    Piccart M; Procter M; Fumagalli D; de Azambuja E; Clark E; Ewer MS; Restuccia E; Jerusalem G; Dent S; Reaby L; Bonnefoi H; Krop I; Liu TW; Pieńkowski T; Toi M; Wilcken N; Andersson M; Im YH; Tseng LM; Lueck HJ; Colleoni M; Monturus E; Sicoe M; Guillaume S; Bines J; Gelber RD; Viale G; Thomssen C;
    J Clin Oncol; 2021 May; 39(13):1448-1457. PubMed ID: 33539215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.